Search

ObjectivesCoronavirus disease-19 (COVID-19)/influenza poses unprecedented challenges to the global economy and healthcare services. Numerous studies have described alterations in the microbiome of COVID-19/influenza patients, but further investigation is needed to understand the relationship between the microbiome and these diseases. Herein, through systematic comparison between COVID-19 patients, long COVID-19 patients, influenza patients, no COVID-19/influenza controls and no COVID-19/influenza patients, we conducted a comprehensive review to describe the microbial change of respiratory tract/digestive tract in COVID-19/influenza patients.MethodsWe systematically reviewed relevant literature by searching the PubMed, Embase, and Cochrane Library databases from inception to August 12, 2023. We conducted a comprehensive review to explore microbial alterations in patients with COVID-19/influenza. In addition, the data on α-diversity were summarized and analyzed by meta-analysis.ResultsA total of 134 studies comparing COVID-19 patients with controls and 18 studies comparing influenza patients with controls were included. The Shannon indices of the gut and respiratory tract microbiome were slightly decreased in COVID-19/influenza patients compared to no COVID-19/influenza controls. Meanwhile, COVID-19 patients with more severe symptoms also exhibited a lower Shannon index versus COVID-19 patients with milder symptoms. The intestinal microbiome of COVID-19 patients was characterized by elevated opportunistic pathogens along with reduced short-chain fatty acid (SCFAs)-producing microbiota. Moreover, Enterobacteriaceae (including Escherichia and Enterococcus) and Lactococcus, were enriched in the gut and respiratory tract of COVID-19 patients. Conversely, Haemophilus and Neisseria showed reduced abundance in the respiratory tract of both COVID-19 and influenza patients.ConclusionIn this systematic review, we identified the microbiome in COVID-19/influenza patients in comparison with controls. The microbial changes in influenza and COVID-19 are partly similar.

The corrosion inhibition behavior of an imidazoline derivative, namely, 2-undecyl-N-carboxymethyl-N-hydroxyethyl imidazoline (UHCI) for carbon steel in 4 wt.% citric acid solutions was characterized by weight loss method and electrochemical techniques in conjunction with X-ray photoelectron spectrometer (XPS) technique. The inhibitor has a good anti-corrosion effect on the carbon steel in 4 wt.% citric acid solutions. The inhibition efficiency increases with UHCI concentrations from 0 up to 0.4 wt.%, yet declines a bit at 0.6 wt.% per contra with further augmentation of concentration. The inhibition efficiency declines with the rise of temperature from 20°C to 95°C, while it rises with the extension of soaking time from 2 h to 24 h. Two N1s peaks that appeared in XPS spectra give proof of UHCI inhibitor adsorbed on the car- bon steel surface. [ABSTRACT FROM AUTHOR]